Wegovy vs Zepbound
These are the two brands licensed in the United States for chronic weight management. Wegovy is semaglutide, from Novo Nordisk. Zepbound is tirzepatide, from Eli Lilly. Both are once-weekly injections, and both sit behind a prescription.
If you have been comparing Ozempic and Mounjaro for weight, these are the products you actually want to be looking at — the diabetes-labeled brands are a different conversation with different coverage rules.
- WegovySemaglutide
- ZepboundTirzepatide
- Both licensed forChronic weight management
- RouteWeekly injection
Side by side
| Wegovy | Zepbound | |
|---|---|---|
| Molecule | Semaglutide | Tirzepatide |
| Receptors engaged | GLP-1 | GIP and GLP-1 |
| Maker | Novo Nordisk | Eli Lilly |
| Route | Weekly subcutaneous injection | Weekly subcutaneous injection |
| Diabetes-labeled sibling | Ozempic | Mounjaro |
Both carry additional licensed uses beyond weight management alone — Wegovy in relation to cardiovascular risk in specific populations, Zepbound in relation to obstructive sleep apnea in adults with obesity. Whether either of those applies to you is exactly the sort of thing that should shape the choice, and exactly the sort of thing only a clinician reviewing your record can judge.
How side effects are handled
We are not going to list symptoms and invite you to self-assess. What is useful to know is the shape of the conversation: both medicines share a broadly similar profile of gastrointestinal effects, both are started at a low level and adjusted upward specifically to manage that, and both carry boxed warnings and contraindications that rule them out for some people entirely.
The contraindications are the part worth preparing for. Certain personal and family medical histories exclude these medicines, and a prescriber will ask about them directly. Bring that history to the appointment rather than trying to work out in advance whether it disqualifies you.
Read the manufacturer's medication guide for whichever you are prescribed, and raise anything you notice with the prescriber rather than adjusting anything yourself.
Cost and coverage
This is where the two genuinely diverge for most people, and not in a way that generalises. Weight-management indications are the most commonly excluded category in US drug coverage, so the first question is not which is cheaper but whether either is covered at all.
- Whether your plan covers weight management as a category. Many exclude it outright regardless of brand.
- Employer carve-outs, which can differ from the insurer's standard formulary.
- Manufacturer savings programs, generally conditional on commercial insurance.
- Direct-from-manufacturer cash pharmacy routes, which exist for some presentations of each brand.
- Whether a self-pay vial presentation is offered rather than the autoinjector, which is priced differently.
Get the number in writing, and ask specifically what it becomes after any introductory period ends.
Which is right for you
There is no general answer, and anyone offering one without your history is guessing. The decision turns on your medical record, the additional licensed uses, what your plan will fund, and which product your prescriber can reliably obtain.
Dosing is determined by a licensed provider.
Questions
Wegovy vs Zepbound: common questions
- Which is better, Wegovy or Zepbound?
- That depends on your medical history, which additional licensed uses are relevant to you, and what your insurance will fund. Both are licensed for chronic weight management; neither is generally superior for everyone.
- Why is one covered and the other not?
- Insurers negotiate separately with each manufacturer and place brands on different formulary tiers. It is common for a plan to cover one weight-management brand and exclude the other.
- Do they have different side effects?
- They share a broadly similar profile, with differences in detail. Both carry contraindications that exclude some people entirely, which is why the medication guide and a prescriber conversation matter more than a comparison table.
- Can I use the diabetes versions instead?
- Ozempic and Mounjaro are licensed for type 2 diabetes, not weight management. Prescribing outside a licensed indication is a clinician's decision and changes how insurers respond.
- Is there a cheaper compounded version?
- Compounded copies were widely available while these drugs were in shortage. The FDA has since declared those shortages resolved, which narrowed the permission to compound them substantially.
Talk to a licensed prescriber about which one fits you
We do not prescribe, and we do not pick for you. We point you at licensed providers who can assess your situation, check your coverage, and tell you what each option would actually mean for you.
Find a licensed prescriberMedical disclaimer
TreatRadar is an information and referral service. We are not a medical provider, we do not practise medicine, and nothing here is medical advice, diagnosis, or a treatment recommendation. Decisions about treatment belong to you and a licensed clinician who knows your history.
We may be compensated when you connect with a provider through this site. That never changes which providers we list or how we describe them — how we verify providers.
Some information (pricing, provider coverage, state rules) may change or await verification — confirm details directly with the provider or the relevant state medical board before booking.